Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Mr. Maizel has served as Chief Commercial Officer since October 2024, previously serving as EVP Head of Commercial. Prior to Axsome, he was VP U.S. Psychiatry at AbbVie and held roles at Allergan, Dendreon, and Johnson & Johnson; he began his career at ArrowPath Venture Partners, an early-stage technology investment fund.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Axsome Therapeutics, Inc.

2026-04-24 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Axsome Therapeutics, Inc.

Open Axsome Therapeutics, Inc. profile →

Director at Axsome Therapeutics, Inc.

2026-04-24 → End not stated

current · source reported

Observed: 2026-09-19

Axsome Therapeutic…Axsome Therapeutics, Inc.Ari Maizel, M.B.A.

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingAXSM DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:ari-maizel-m-b-a-axsm
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

AI expertise · Source reportedAI expertise: not identified in the cited filing1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

AI governance relevance · Source reportedAI governance relevance: not identified in the cited filing1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Axsome Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive company · CorroboratedExecutive at Axsome TherapeuticsSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive function · Source reportedOther Executive (OTHER_EXECUTIVE)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · CorroboratedExecutive title: Chief Commercial OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

View all sources4 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1579428/000119312526177610/axsm-20260424.htm

    Sec Proxy · Tier not stated · Reviewed Sep 2, 2026

    Supports: Director at Axsome Therapeutics, Inc. (NASDAQ: AXSM)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title

  4. https://www.sec.gov/Archives/edgar/data/1579428/000119312526177610/axsm-20260424.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership